Hutchmed (China) Limited 30 August 2024 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Hong Kong, Shanghai...
Hutchmed (China) Limited 22 August 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent...
Hutchmed (China) Limited 21 August 2024 Press Release HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia Hong Kong, Shanghai...
Hutchmed (China) Limited 06 August 2024 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong...
Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology ...
Hutchmed (China) Limited 31 July 2024 HUTCHMED Reports 2024 Interim Results and Provides Business Updates Hong Kong, Shanghai & Florham...
Ltd - Hong Kong-based pharmaceutical company - Says new drug application for tazemetostat given priority review by the ...
Hutchmed (China) Limited 04 July 2024 Press Release HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of...
Hutchmed (China) Limited 28 June 2024 Press Release Overseas Regulatory Announcement: Filing of Form F-3 Hong Kong, Shanghai &...
Hutchmed (China) Limited 28 June 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ ¡X Friday, June 28, 2024: HUTCHMED...
Hutchmed (China) Limited 28 June 2024 Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Friday, June 28, 2024:...
Hutchmed (China) Limited 26 June 2024 HUTCHMED to Announce 2024 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed (China) Limited 24 June 2024 Press Release Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 - HUTCHMED will...
Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notifica ...
Hutchmed (China) Limited 24 June 2024 HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads